NeoGenomics, Inc. (NASDAQ:NEO) announced its first quarter 2021 financial results will be released on May 5, 2021. The company will host a conference call and webcast at 8:30 AM EDT the same day to discuss these results. Investors are encouraged to join by calling the specified numbers for domestic and international participants. A replay of the call will be available until May 19, 2021. Headquartered in Fort Myers, FL, NeoGenomics specializes in cancer-focused genetic testing and offers a comprehensive testing menu for oncologists and pathologists.

NeoGenomics, Inc. (NASDAQ:NEO) announced its acquisition of Intervention Insights, Inc. (d/b/a Trapelo Health) for $65 million, combining $35 million in cash and $30 million in stock. Expected to close in April 2021, this deal enhances NeoGenomics' capabilities in precision oncology through Trapelo's innovative decision-support platform. This platform enables efficient treatment selection and clinical trial matching, aligning patient diagnostics with clinical guidelines. The acquisition aims to broaden access to quality cancer care.

NeoGenomics (NASDAQ:NEO) has partnered with Elevation Oncology to enhance patient identification for the Phase 2 CRESTONE study focusing on solid tumors with NRG1 gene fusions. NRG1 fusion incidence is estimated at 0.2% across all solid tumors, making efficient detection crucial. NeoGenomics conducts over 50,000 next-generation sequencing tests annually, which will aid in matching patients to targeted therapies. The collaboration aims to improve precision oncology for patients, ensuring actionable treatment opportunities in ongoing clinical trials.

NeoGenomics (NASDAQ: NEO) and Elevation Oncology announced a collaboration to improve the identification of patients with solid tumors that have NRG1 gene fusions. This partnership aims to enroll eligible patients in the Phase 2 CRESTONE study, targeting the treatment of these rare genetic alterations. NRG1 fusions are found in approximately 0.2% of solid tumors and are actionable targets for precision oncology. The collaboration reflects a commitment to enhance diagnostic capabilities and patient outcomes in oncology.

NeoGenomics, Inc. (NASDAQ:NEO) will present at the Virtual Raymond James 42nd Annual Institutional Investors Conference on March 3, 2021, at 10:50 AM ET. CFO Kathryn McKenzie and Chief Strategy Officer Doug Brown will discuss the company's cancer-focused genetic testing services. The presentation will be available via webcast on the company's website. NeoGenomics specializes in oncology testing and supports pharmaceutical clients in clinical trials. The company operates multiple accredited laboratories across the U.S. and internationally.

NeoGenomics, Inc. (NASDAQ:NEO) will present at the Virtual 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 10:00 AM ET. Key executives, including CEO Douglas VanOort and CFO Kathryn McKenzie, will be involved in the presentation. The event will be webcast live, accessible via the company’s investor relations page. NeoGenomics specializes in cancer genetic testing and serves a wide range of healthcare providers and pharmaceutical firms globally. For more information, visit www.neogenomics.com.

NeoGenomics reported a record revenue of $126 million for Q4 2020, an 18% increase year-over-year. Clinical Services revenue rose 14% to $107 million, boosted by $9 million in COVID-19 testing. Pharma Services revenue surged 43% to $19 million with a backlog growth of 60% to $209 million. Although net income for 2020 declined to $4 million from $8 million in 2019, adjusted EBITDA fell to $35 million from $57 million. The company completed stock and convertible note offerings, generating $553 million for corporate growth and acquisitions.

NeoGenomics, Inc. announces a leadership transition with Mark Mallon set to become CEO on April 19, 2021, succeeding Douglas M. VanOort, who will assume the role of executive chairman. VanOort, who led the company for 12 years, helped grow revenues from $20 million to approximately $500 million, and increased market capitalization from $26 million to over $6 billion. Mallon, previously CEO of Ironwood Pharmaceuticals, brings extensive experience from AstraZeneca. The change aims to build on NeoGenomics' strong competitive position in oncology testing and enhance value for stakeholders.

NeoGenomics, Inc. (NASDAQ:NEO) will participate in the BTIG Virtual Medtech, Digital Health, Life Science & Diagnostic Tools Conference on February 19, 2021 at 9:30am ET. Presenters include CEO Douglas VanOort, CFO Kathryn McKenzie, and Chief Strategy Officer Doug Brown. The event will be available via live webcast on the company's investor relations website. NeoGenomics specializes in cancer genetics testing and provides comprehensive services for diagnostics and drug development for various healthcare entities worldwide.